Who are Sensipar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): L-Tryptophan, Upasita, Orkedia, Parsabiv.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cinacalcet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sensipar — Competitive Intelligence Brief

Sensipar (CINACALCET) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium-sensing Receptor Agonist. Area: Oncology.

marketed Calcium-sensing Receptor Agonist Extracellular calcium-sensing receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sensipar (CINACALCET) — Amgen. Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sensipar TARGET	CINACALCET	Amgen	marketed	Calcium-sensing Receptor Agonist	Extracellular calcium-sensing receptor	2004-01-01
L-Tryptophan	TRYPTOPHAN		marketed	tryptophan	Myeloperoxidase, Extracellular calcium-sensing receptor, Probable G-protein coupled receptor 139
Upasita	UPACICALCET	SANWA KAGAKU KENKYUSHO Co., Ltd.	marketed		Extracellular calcium-sensing receptor
Orkedia	EVOCALCET	Kyowa Hakko Kirin Co., Ltd.	marketed		Extracellular calcium-sensing receptor
Parsabiv	ETELCALCETIDE	Kai Pharms Inc	marketed	Calcium-sensing Receptor Agonist	CaSR	2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium-sensing Receptor Agonist class)

Amgen · 1 drug in this class
Kai Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sensipar — Competitive Intelligence Brief. https://druglandscape.com/ci/cinacalcet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab